1. Home
  2. IIIN vs CTNM Comparison

IIIN vs CTNM Comparison

Compare IIIN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IIIN

Insteel Industries Inc.

N/A

Current Price

$30.58

Market Cap

484.9M

Sector

Industrials

ML Signal

N/A

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

N/A

Current Price

$17.14

Market Cap

550.7M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
IIIN
CTNM
Founded
1953
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Steel/Iron Ore
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
484.9M
550.7M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
IIIN
CTNM
Price
$30.58
$17.14
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
128.7K
534.3K
Earning Date
04-16-2026
05-13-2026
Dividend Yield
4.37%
N/A
EPS Growth
112.12
0.46
EPS
1.12
N/A
Revenue
$647,706,000.00
N/A
Revenue This Year
$14.20
N/A
Revenue Next Year
$6.82
N/A
P/E Ratio
$27.09
N/A
Revenue Growth
22.39
N/A
52 Week Low
$24.35
$8.60
52 Week High
$39.91
$17.51

Technical Indicators

Market Signals
Indicator
IIIN
CTNM
Relative Strength Index (RSI) 48.19 62.30
Support Level $30.49 $13.65
Resistance Level $31.04 N/A
Average True Range (ATR) 0.72 0.86
MACD -0.14 0.07
Stochastic Oscillator 37.01 96.43

Price Performance

Historical Comparison
IIIN
CTNM

About IIIN Insteel Industries Inc.

Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: